Asmadil

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Asmadil

Property Description
Active ingredient Salbutamol (also known as Albuterol)
Form Metered-dose inhaler (MDI), Nebulizer solution, Tablets
Pharmacological class Short-acting beta-agonist (SABA)
General purpose Rapid relief of restricted airflow
Origin Synthetic compound

Asmadil is a synthetic, prescription-only medicinal preparation whose active therapeutic component is Salbutamol, a compound utilized to quickly relieve constricted airways. It is a foundational medicine in respiratory care, classified as a bronchodilator due to its specific action on the muscles lining the air passages. Asmadil is specifically recognized for its formulation as a metered-dose inhaler (MDI), a delivery method that is clinically favored for its portability and speed of access.


What Type of Medicine is Asmadil (Salbutamol)?

Asmadil belongs to the Short-acting beta-agonist (SABA) pharmacological class, designated as a rapidly acting agent used for immediate relief. Its scientific mechanism involves functioning as a selective beta2-adrenergic agonist. This active substance acts as a relaxant on the smooth muscles surrounding the air passages. The international nonproprietary name for this active compound is Salbutamol, which is also frequently identified as Albuterol in the United States.


Composition and Available Forms of Asmadil

The preparation is a single-ingredient product whose primary component is the chemical substance Salbutamol (or Salbutamol sulfate salt, C13H21NO3). This active substance is made available in several pharmaceutical preparations, most commonly as a metered-dose inhaler (MDI) and an aqueous nebulizer solution. While multiple forms exist, the primary and most direct route of administration for acute relief remains inhalation, facilitating rapid delivery to the target site.


What is the General Purpose of a Bronchodilator?

The general purpose of Asmadil is to rapidly restore the proper airflow within the lungs by directly addressing the physical restriction of the airways. This is achieved through the fundamental action of inducing the relaxation of smooth muscle and subsequent bronchodilation. This mechanism serves the critical function of providing immediate and temporary symptomatic relief in scenarios where rapid relief is necessary, such as during sudden shortness of breath.

Regulatory References

  1. NIH: MedlinePlus
  2. World Health Organization (WHO)

What side effects are possible with Asmadil?

Possible side effects and safety information

The safety profile for Asmadil (Salbutamol) is established through official regulatory documents, which categorize potential adverse reactions by their frequency and the body system affected. These classifications ensure that risks, both common and rare, are clearly defined in official prescribing information.

Frequency-Classified Adverse Reactions

Adverse reactions are formally grouped by how often they may occur, according to regulatory standards:

  • Common: Tremor, headache, tachycardia (increased heart rate), palpitations, and muscle cramps.
  • Uncommon: Irritation of the mouth and throat (following inhalation).
  • Rare: Hypokalemia (low blood potassium), arrhythmias, peripheral vasodilation, and serious hypersensitivity reactions, including angioedema and collapse.
  • Very Rare: Paradoxical bronchospasm (immediate, severe worsening of breathing) and hyperactivity.

Systemic Safety Patterns

Adverse reactions are classified by the physiological system they involve. Common effects frequently involve the Nervous system (tremor, headache) and Cardiac system (tachycardia, palpitations). Rare but serious effects may involve the Metabolism and nutrition system (hypokalemia) and the Immune system (hypersensitivity).

Specific safety considerations exist for certain groups. Caution is advised in patients with pre-existing conditions such as cardiovascular disease, hypertension, hyperthyroidism, and diabetes mellitus (due to reported increases in blood glucose). Certain effects, such as tremor and headache, are often noted as being transient and may lessen with continued use, while cardiac effects and hypokalemia are more frequently associated with higher doses.

Overdose and Emergency Response

Overdose and When to Seek Help

Overuse of Asmadil (Salbutamol) can lead to an over-exaggeration of the drug's effects, and official regulatory documents warn that excessive use may be fatal.

Documented Overdose Presentations

Symptoms of an overdose are typically related to excessive beta-adrenergic stimulation and may include:

System Official Manifestations
Cardiovascular Tachycardia (rapid heart rate), palpitations, cardiac arrhythmias, myocardial ischaemia (documented in post-marketing reports).
Nervous System Tremor (skeletal muscle tremor), headache, and nervousness or CNS stimulation.
Metabolic Potentially serious Hypokalemia (low serum potassium), hyperglycemia, and lactic acidosis.

Required Emergency Actions

The most important guidance from regulatory sources is to seek immediate medical attention if you suspect an overdose or if you experience severe, life-threatening symptoms. Urgent action is specifically required if:

  • Signs of overdose (such as severe palpitations or pronounced tremor) are present.
  • You experience paradoxical bronchospasm—a sudden, life-threatening worsening of breathing—which requires immediate discontinuation of the medicine and alternative therapy.
  • You need to use more doses than usual, as this may be a sign of worsening asthma that requires urgent re-evaluation of your treatment regimen.

Overdose management is symptomatic and supportive, often requiring continuous monitoring of cardiac function (ECG), serum potassium levels, and blood sugar in a clinical setting.

Therapeutic Uses of Asmadil

Main Uses and Benefits of Asmadil

Asmadil is a therapeutic agent primarily utilized for the management of respiratory conditions characterized by airflow obstruction and bronchospasm. Its active component belongs to a class of medications designed to relax the smooth muscles of the airways, facilitating easier breathing.

Primary Indications

The medication is indicated for the following conditions:

  • Bronchial Asthma: It is used to provide rapid relief from acute symptoms such as wheezing, chest tightness, and shortness of breath. It is also employed to prevent exercise-induced bronchospasm.
  • Chronic Obstructive Pulmonary Disease (COPD): It assists in managing the reversible component of airway obstruction in patients with chronic bronchitis and emphysema.
  • Acute Bronchospasm: It is used to treat sudden narrowing of the airways caused by various triggers or underlying respiratory illnesses.

Therapeutic Benefits

The clinical benefits of Asmadil focus on improving respiratory function and enhancing the patient's quality of life through the following mechanisms:

  • Rapid Bronchodilation: The medication acts quickly after administration to widen the airways, providing prompt relief during respiratory distress.
  • Improved Airflow: By reducing the resistance in the respiratory tract, it allows for a more efficient exchange of oxygen and carbon dioxide.
  • Symptom Prevention: When used before physical exertion or exposure to known allergens, it can help prevent the onset of breathing difficulties.
  • Support for Chronic Management: While it focuses on acute relief, its role in a broader management plan helps maintain airway patency and reduces the severity of daily respiratory symptoms.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility to use Asmadil (Salbutamol) is strictly defined by official regulatory bodies based on age, existing medical conditions, and known allergies.

Absolute Contraindications

The medicine is strictly prohibited for patients with a documented allergy or hypersensitivity to salbutamol or any ingredient in the specific formulation. The medicine is also contraindicated for a specific obstetrical use: arresting premature labor (tocolysis).

Age-Related Eligibility

Use is officially established for adults and children aged 4 years and older. Conversely, the safety and effectiveness of the metered-dose inhaler formulation have not been established in children younger than four years of age.

Restricted and Conditional Use

Official labels specify that Asmadil must be used with caution in patients who have pre-existing cardiovascular disorders (including hypertension and arrhythmias), diabetes mellitus, thyrotoxicosis (overactive thyroid), or convulsive disorders. Similarly, regulatory guidance advises that use during pregnancy or lactation should only proceed after careful assessment, as the medicine may be secreted in breast milk and should only be administered if the benefit justifies the potential risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents describe several interaction patterns for Asmadil (Salbutamol) based on pharmacodynamic and pharmacokinetic effects.

Contraindicated and Restricted Combinations

Co-administration with non-selective beta-adrenergic blocking agents, such as Propranolol, is officially restricted. This combination is noted to block the effects of Salbutamol and may risk severe bronchospasm. Co-use with other short-acting sympathomimetic aerosol bronchodilators is not recommended due to the potential for additive deleterious cardiovascular effects.

Interactions Affecting the Vascular and Electrolyte Systems

Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs) may potentiate the vascular effects of Salbutamol, increasing the risk of cardiovascular adverse events. Interactions with non-potassium-sparing Diuretics, Xanthine Derivatives, and Corticosteroids are documented to potentiate the risk of hypokalemia (low serum potassium). Concurrent use with Corticosteroids may also exaggerate the increase in blood glucose levels, a consideration noted for patients with diabetes.

Timing and Drug Exposure

A mandatory timing restriction applies to surgical procedures involving Halogenated Anaesthetics; Salbutamol should not be used for at least six hours prior to the planned administration of these agents due to the risk of severe dysrhythmia and hypotension. Salbutamol may also cause a decrease in the serum concentration of Digoxin.

Mechanism of Action

Selective beta2-Receptor Activation and Bronchial Relaxation

The primary mechanism involves selective agonism at the beta2-adrenergic receptors found predominantly on the bronchial smooth muscle cells. This targeted interaction initiates the Gs-protein signaling cascade, resulting in a rapid surge of the second messenger, cyclic AMP (cAMP), within the cell. The subsequent inactivation of Myosin Light-Chain Kinase (MLCK) halts the muscle's ability to contract, causing the bronchial smooth muscle to relax. This physiological change is the structural alteration that results in an increased diameter of the airway lumen and a subsequent decrease in airflow resistance.


Constraints of the Muscle-Targeted Mechanism

While responsive to dynamic airway constriction, the mechanism is fundamentally constrained by factors outside of muscle tone. Continuous receptor stimulation can lead to tachyphylaxis (receptor desensitization), reducing the magnitude of the maximal physiological effect. Furthermore, the action exerts less influence when the physical restriction of the airways is caused by structural factors like edema, extensive mucus plugging, or irreversible tissue remodeling, as these barriers are independent of the beta2-mediated smooth muscle relaxation.

Dosage and Administration Information

Official Administration Guidelines for Asmadil (Salbutamol)

Asmadil contains salbutamol, and its administration follows specific guidelines for its dosage forms, which may include Inhalers, Tablets, or Syrup. These instructions define the correct route, dose, and technique for use.

Administration Element Adult and Adolescent Instructions (Inhaler) Children (4–11 years) Instructions (Inhaler)
Route of Administration Oral Inhalation only Oral Inhalation only
Dosing for Symptoms 1 to 2 inhalations, repeated every 4 to 6 hours as needed. 1 inhalation, may be increased to 2 if required.
Dosing for Prevention 2 inhalations 15 to 30 minutes before exercise. 1 to 2 inhalations 15 minutes before exercise.
Maximum Frequency Not recommended to exceed 8 inhalations in a 24-hour period. Not recommended to exceed 4 to 8 inhalations in a 24-hour period.

Procedural Requirements

The correct use of a metered-dose inhaler requires specific steps to ensure the medicine reaches the lungs effectively:

  • Priming: If the inhaler is new or has not been used for more than two weeks, the device must be primed by releasing four test sprays into the air, shaking well before each spray.
  • Technique: Shake the inhaler well before each use. Breathe out fully, place the mouthpiece in your mouth, and start breathing in slowly while firmly pressing down on the canister. Hold your breath for about 10 seconds before exhaling.
  • Cleaning: The inhaler actuator must be washed with warm water and air-dried completely at least once a week to prevent medicine buildup.

For missed doses of a scheduled regimen (e.g., tablets/syrup), the missed dose should be taken as soon as remembered. However, if it is nearly time for the next dose, the missed dose should be skipped, and the regular schedule resumed. Double dosing to compensate is not recommended.

Recent Clinical Evidence

Research evidence / Overview of studies

This overview is a summary of research findings related to the agent's use in clinical trials. This information is descriptive only and does not constitute medical advice or a recommendation for treatment. It is not an interpretation of clinical suitability.


Key Study Findings

Studies have investigated whether the agent is associated with changes in recovery speed and symptom presentation in adults with this condition. The primary research goal was to evaluate clinical outcomes in study participants.

  • Symptom Severity: Researchers explored outcomes related to the severity of chronic symptoms.
  • Duration of Recovery: Trials documented the time it took for participants to meet pre-defined recovery milestones.
  • Quality of Life: The impact on patient-reported quality of life metrics was assessed in several observational studies.

Specific Research Areas

Comparison Studies

One study compared the outcomes associated with the agent to those of an existing treatment method in a small group of participants. A meta-analysis focused on comparing the overall study design and measured outcomes of various independent trials. No head-to-head randomized controlled trials (RCTs) were available for inclusion in the initial review.

Combination Use

Research has also examined the agent’s use alongside other treatments. In these studies, the combination was evaluated for whether it is associated with changes in inflammatory markers over a 12-week period. Research has evaluated whether the agent is associated with the rate of recurrence.

Safety and Tolerability Profile

Clinical trials have assessed the safety profile across diverse participant groups.

  • Adverse Events: The most frequently reported adverse events in the studies were mild and included headache and gastrointestinal upset. No serious adverse events were statistically associated with the agent’s exposure in the primary trial.
  • Long-Term Use: Studies have also examined the profile of the agent during long-term use. Specific populations, including individuals with pre-existing conditions, were excluded from some studies.

Mechanism of Action Focus

Studies investigated the relationship between the agent and measures of inflammation, and assessed patient-reported pain scores. Researchers in clinical trials have assessed outcomes related to symptom resolution over the study period. Study authors noted the need for further research regarding the agent's activity.

Key Studies & References

  1. Global Initiative for Asthma (GINA) Pocket Guide: Diagnosis and Management
  2. 2020 Focused Updates to the Asthma Management Guidelines: National Heart, Lung, and Blood Institute (NHLBI)

Frequently Asked Questions (FAQ)

Common questions about Asmadil (FAQ)


Q: How quickly does Asmadil start working after I take it?

A: According to official product information, Asmadil is designed for rapid relief. Its fast onset of action typically results in the opening of the airways, known as bronchodilation, within about 5 minutes following inhalation.


Q: How long do the effects of Asmadil usually last?

A: The effects of the inhaled medicine are generally short-acting. Official studies and product labels indicate that the duration of action, providing symptomatic relief, typically lasts for 4 to 6 hours in most patients.


Q: Can taking Asmadil make you gain weight over time?

A: Weight gain is not listed among the commonly reported or frequently associated adverse events found in the official product information or clinical trial data for this medication. The known safety profile does not include weight changes as a common concern.


Q: Should I avoid caffeine while I'm using Asmadil?

A: Both the medicine and caffeine can stimulate the body and increase heart rate and blood pressure. Combining the two may enhance these effects, potentially leading to symptoms like heart palpitations or a shaky feeling. Patients with pre-existing heart conditions may wish to consult with a healthcare professional regarding combination use.


Q: Can I use Asmadil during pregnancy or while breastfeeding?

A: Official guidance specifies that use during pregnancy is advised only after careful assessment, where the anticipated benefit is determined to outweigh the potential risk to the fetus. The active ingredient is also likely secreted in breast milk, and use while nursing is generally not recommended unless the benefits are medically justified.


Q: Does Asmadil affect blood pressure or blood sugar levels?

A: Yes, official warnings note that Asmadil may cause clinically significant changes in systolic and diastolic blood pressure in some people. It may also affect pre-existing diabetes mellitus because it can lead to reported increases in blood glucose (sugar) levels.


Q: What happens if I forget to take a dose of Asmadil?

A: If you are using a scheduled form (like a tablet or syrup) and realize you missed a dose, you should skip the missed dose if it is almost time for your next one. Official guidance states that taking a double dose to compensate for a missed one is not recommended.


Q: Does Asmadil lose effectiveness the longer you use it?

A: Official warnings note that the need for increasing use of the drug to relieve symptoms indicates a deterioration of asthma control. Continuous stimulation of the receptors in the airways can also lead to a temporary reduction in responsiveness, a process known as tachyphylaxis.


Q: Does Asmadil interact with birth control pills?

A: Regulatory drug interaction databases have not documented any formal interactions between the active ingredient (Albuterol/Salbutamol) and common progestin-containing oral contraceptives. It is still appropriate to review all medications with a healthcare provider.


Q: Is Asmadil safe to use if I have a history of glaucoma?

A: Official guidelines advise caution and special monitoring for use in patients who have or are at risk of narrow-angle glaucoma. Product labeling includes a precaution advising that the medicine should not be allowed to enter the eyes.


Q: Is Asmadil used only for asthma, or does it treat other breathing problems?

A: The drug is indicated for the treatment and prevention of sudden, temporary airway restriction, or bronchospasm. This includes the relief of acute symptoms in people with asthma as well as in those with other chronic breathing conditions, such as Chronic Obstructive Pulmonary Disease (COPD).


Q: Is there a generic version of Asmadil available?

A: Asmadil is a brand name product. The active ingredient is Salbutamol, which is also frequently identified as Albuterol in the United States. This substance is widely available under various brand names and as a standard generic medicine.


Q: What happens if you accidentally swallow some of the Asmadil spray?

A: When used correctly, a small portion of the medicine is naturally swallowed and absorbed through the gut. However, accidentally swallowing a large amount of the spray may increase the potential for systemic effects like tremors and a rapid heart rate. Individuals experiencing pronounced symptoms may wish to seek medical attention.


Q: Are there different strengths or versions of the Asmadil medication?

A: Yes, the medicine is supplied in different dosage forms, such as the metered-dose aerosol inhaler and an aqueous nebulizer solution. While the standard dosage per puff is generally fixed, the medication is also supplied in different canister sizes.


Q: Can I travel internationally with my Asmadil inhaler?

A: Official regulatory advice for travelers suggests keeping your medicine in its original container with the dispensing label and prescription. Carrying a written statement from the prescribing physician is sometimes recommended to assist with international medication requirements.


Q: Is Asmadil likely to show up on a standard drug test?

A: The use of the drug may lead to positive results in tests for non-clinical substance abuse. This is particularly relevant in the context of professional athletic performance enhancement (doping) testing, where specific rules apply to its use.


Q: What is the shelf life of an Asmadil inhaler once it's opened?

A: The shelf life is defined by the manufacturer. A common instruction for the metered-dose inhaler is to discard the product 13 months after opening the foil pouch, or once the dose counter indicates zero doses remaining, whichever occurs first.


Q: What's the difference between the powder and the aerosol forms of Asmadil?

A: Both the aerosol (spray) and inhalation powder forms deliver the same active ingredient (Salbutamol) to the lungs. The key difference is the specific delivery device and the distinct technique required for effective administration of each form.

How should Asmadil be stored and disposed of?

How to Store and Dispose of Asmadil (Salbutamol)

The storage and disposal instructions for Asmadil are defined by regulatory labeling to ensure product stability and safety. The metered-dose inhaler (MDI) must be kept at controlled room temperature, specifically between 59°F and 77°F (15°C to 25°C).

Storage Constraints

Condition
Protect the MDI canister from freezing and from temperatures exceeding 120°F; high heat can cause bursting.
Keep the medicine in its original container and ensure it is tightly closed to protect it from moisture and light.
Store the medication out of the sight and reach of children.

Disposal Requirements

Expired or unused product must be disposed of according to regulatory guidelines. The preferred method is to utilize drug take-back programs when available. The MDI canister must not be punctured, incinerated, or thrown directly into household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Asmadil found in:

A-Z Index: